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a  b  s  t  r  a  c  t
The  worldwide  increasing  prevalence  of  type  2  diabetes  mellitus  (T2DM)  poses  an immense  public  health
hazard  leading  to  a variety  of  complications  such  as cardiovascular  diseases,  nephropathy  and  neurop-
athy.  Diet,  as  a  key  component  of a healthy  human  lifestyle,  plays  an  important  role  in  the  prevention  and
management  of  T2DM  and  its complications.  The  dietary  n-3 polyunsaturated  fatty  acids  (PUFAs)  have
been  associated  with  various  favourable  functions  such  as  anti-inﬂammatory  effects,  improving  endothe-eywords:
ype 2 diabetes mellitus
-3 PUFAs
pidemiological studies
linical studies
lial  function,  controlling  the  blood  pressure,  and  reducing  hypertriglyceridemia  and  insulin  insensitivity.
According  to some  epidemiological  studies,  a lower  prevalence  of  T2DM  was  found  in  populations  con-
suming  large  amounts  of seafood  products,  which  are  rich  in  n-3  PUFAs.  However,  the  evidence  on  the
relation  between  ﬁsh  intake,  dietary  n-3  PUFAs,  and  risk  of  T2DM  is  controversial.  Therefore,  this  paper
aimed  to review  the  epidemiological  and  clinical  studies  on  the  role  of  dietary  n-3  PUFAs  in T2DM.  Also,
the limitations  of these  studies  and  the  need  for potential  further  research  on  the  subject  are  discussed.© 2013 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Diabetes has become a worldwide problem leading to blindness,
enal failure and lower limb amputation. Moreover it is a signiﬁcant
isk factor for coronary heart disease and stroke [1,2]. The number
f adults with diabetes in the world is thought to increase from
85 million (6.4%) in 2010 to 439 million (7.7%) in 2030 [3].  Insulin
muscle (glucose uptake), liver (inhibition of gluconeogenesis) and
fat cells (inhibition of lipolysis) [4–6]. There are several factors con-
tributing to the development of insulin resistance and T2DM such
as genetic predisposing factors, diet, activity of antibodies against
insulin and its receptors, stress and inﬂammation [6,7].
n-3 polyunsaturated fatty acids (PUFAs) are long-chain fatty
acids found in seafood products such as ﬁsh and shellﬁsh, andesistance is a major problem in type 2 diabetes mellitus (T2DM)
nd is determined by normal amounts of insulin failing to main-
ain normal blood glucose because of decreased responsiveness of
∗ Corresponding author at: Food Security Research Center, Isfahan University of
edical Sciences, Isfahan, Iran. Tel.: +98 311 792 2791; fax: +98 311 6682509.
E-mail address: azadbakht@hlth.mui.ac.ir (L. Azadbakht).
378-5122/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.maturitas.2013.01.008plant products such as nuts, soybean, ﬂaxseed, linseed, canola and
mustard. Unlike saturated fatty acids (SFAs), long-chain n-3 PUFAs
have an important impact in human nutrition, disease prevention
and health promotion [6].  Most of the in vivo studies declare
anti-inﬂammatory effects of n-3 PUFAs, however it is controversial
in clinical trials [8–10]. Therefore, they may  be useful to prevent
or at least reduce insulin resistance and diabetes [5].  The most
important long-chain n-3 PUFAs are eicosapentaenoic acid (EPA),
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ocosahexaenoic acid (DHA), and -linolenic acid (ALA). Moreover,
LA is the precursor of DHA and EPA [9,11].  It can be converted
o DHA and EPA by -6 desaturase/elongase and -5 desat-
rase/elongase, respectively. However, the conversion efﬁciency
s very limited [9,11,12]. Seafood products are the main sources of
HA and EPA, while ALA mainly originates from plant products [9].
Dietary composition plays an important role in reducing risk of
iabetes [13]. The role of dietary fat in T2DM has been reported for
any decades. It has been stated that populations in which peo-
le have high intakes of ﬁsh had lesser risk of diabetes, because
f the effect of n-3 PUFAs in controlling and even preventing the
iabetes [12]. Owing to the fact that n-3 PUFAs are an important
omponent of phospholipids in cell membrane, they can have fun-
amental effects on insulin transduction signals [10,14].  Also, n-3
UFAs may  control the expression of various metabolic genes e.g.
enes involved in glucose metabolism [15].
This paper aimed to review the epidemiological and clinical
tudies regarding the effects of dietary n-3 PUFAs on T2DM and
nsulin sensitivity. Moreover, we discussed the limitations of these
tudies and the possible further researches in this ﬁeld.
. Epidemiological studies
Table 1 summarizes the results of some epidemiological studies
egarding the effects of dietary n-3 PUFAs on T2DM. Epidemio-
ogical studies have demonstrated a lower prevalence of impaired
lucose tolerance and T2DM in populations with consumption of
sh products [16,17].  n-3 PUFAs may  decrease insulin resistance
rough a number of mechanisms such as decrease in plasma trigly-
erides and perhaps small dense lipoproteins [5].  It has been proved
hat substituting SFAs with unsaturated fats such as n-3 PUFAs may
ave beneﬁcial effects on insulin sensitivity and may reduce the risk
f T2DM incidence from impaired glucose tolerance state [18,19].
.1. Prospective cohort studies
Intake of n-3 PUFAs originating from various marine sources is
ither unrelated to diabetes incidence or modestly increases its risk
s testiﬁed by prospective cohort studies [20–22].  In contrast, total
nd n-6 PUFAs seem to have protective effects [22,23]. In an EPIC-
orfolk cohort study, consumption of one or more portion/week of
hellﬁsh (as a source of n-3 PUFAs) increased the risk of diabetes
24]. The reported risks might be due to unhealthy oils rich in both
aturated and trans fatty acids used for frying ﬁsh or shellﬁsh, envi-
onmental contamination of marine products, the type and amount
f cooking fat used, and the possible accompanying condiments
ith which these products are often served such as mayonnaise
r butter [13,25].  In contradiction to the above mentioned results,
pidemiological studies among Alaskan Eskimos (known for a very
igh intake of n-3 PUFAs) has shown a low prevalence of diabetes
16,26].
In a 30-year follow up survey of Dutch and Finnish cohort of the
even Countries Study, it was found that an increase of 8 g/1000 kcal
n ﬁsh consumption (from 7 to 15 g/1000 kcal) inversely affected
he blood glucose level [19]. Other studies reported that consuming
ne or more portion versus less than one portion/week of ﬁsh (either
hite or oily ﬁsh) was associated with a lower risk of diabetes
17,24]. In contrast, several studies demonstrated that n-3 PUFAs
id not reduce the risk of T2DM [20,21,23,27].  A large prospective
tudy reported that the relative risk of T2DM was slightly higher for
omen who had 5 servings or more of ﬁsh meal/week compared tohose who had one serving/month, after adjusting the other dietary
nd lifestyle risk factors [20]. It was suggested that some toxins
uch as dioxins and methyl mercury may  interrupt the insulin
ctions [13]. Furthermore, high-dose consumption of n-3 PUFAs74 (2013) 303– 308
can lower glucose utilization and increase glucagon stimulated C-
peptide [28]. In one study, the role of n-3 PUFAs originating from
either marine or non-marine sources on the development of T2DM
was investigated. It was found that consumption of marine sources
of n-3 PUFAs (range, 0.11–0.6 g/day) was not associated with T2DM
risk. However, non-marine sources of n-3 PUFAs (range, 0.27 to
1.06 g/day) decreased the risk of T2DM [21]. A case-cohort study,
nested within the European Prospective Investigation into Cancer
and Nutrition (EPIC) study, reported that lean ﬁsh consumption
(range of intake, 38.1–139.7 g/week) and total ﬁsh consumption
(range of intake, 19.8–244.4 g/week) were not associated with inci-
dence of T2DM, but fatty ﬁsh intake (range, 4.1–102.6 g/week) had
weakly inverse association with this disease [29]. A recent meta-
analysis on 24 prospective cohort studies found that marine n-3
PUFAs have beneﬁcial effects on the prevention of T2DM in Asian
populations, but not in Western populations [30]. This contradic-
tion might be due to differences in gene–diet interaction, life style
and ﬁsh cooking methods [13,31].
Contradicting data are reported about the effects of dietary n-
3 PUFAs on T2DM. However, the anti-inﬂammatory effects of n-3
PUFAs on cell membrane function and also insulin transduction
signalling has been proved [5].  Therefore, the exact role of n-3
PUFAs intake from various foods in T2DM merits further investi-
gations.
2.2. Cross-sectional and case–control studies
Case–control and cross-sectional studies have reported that
recently diagnosed diabetic patients and subjects with undiag-
nosed T2DM consumed higher SFAs than healthy subjects. It might
be due to not having the chance to change their diet compared
with diabetic patients who  had dietary treatment due to their
disease [31]. Cross-sectional studies in which clamp technique is
used to measure insulin sensitivity and fatty acid composition in
skeletal muscle demonstrated a direct relationship between insulin
action and the proportion of long-chain n-3 PUFAs. Moreover, these
studies found an inverse relationship between SFA content of the
membrane and insulin sensitivity [32,33].  A large cross-sectional
study of elderly Swedish men  indicated that linoleic acid content
of adipose tissue could be a good biomarker of n-6 PUFAs intake
which was  a protective factor for diabetes [34].
It is important that cross-sectional and case–control studies
require cautious interpretation because of multiple sources of bias
and the existence of confounders [31]. Furthermore, epidemiolog-
ical studies using food frequency questionnaires or food records
have a lower reliability compared with those in which biomarkers
of intake such as fatty acid pattern in plasma or biological mem-
branes are used to assess dietary fat intake [24,27].
3. Clinical studies
Several human clinical trials on the effects of n-3 PUFAs among
participants with T2DM are summarized in Table 2. Most studies
showed no effect of n-3 PUFAs supplementation on insulin sensi-
tivity [35–38].  In these studies, the doses of ﬁsh oil and n-3 PUFAs
supplement (EPA + DHA) were 3–3.6 g/day and 1.2–1.68 g/day,
respectively, with the treatment duration of 8–12 weeks. Some
studies declared the adverse effects of n-3 PUFAs supplementation
in high doses (≥5 g/day) [28,39]. However, beneﬁcial effects of n-3
PUFAs supplements on insulin sensitivity are reported in few stud-
ies [40,41]. Due to the small sample size in these 2 studies, the
results of these studies cannot be reliable. In another study, Ramel
et al. [42] showed that consumption of ﬁsh oil capsules (provided
1.3 g/day of n-3 PUFAs) for 8 weeks decreased fasting blood glucose
and insulin resistance in 278 overweight and obese participants.
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Table 1
Epidemiological studies on effects of dietary n-3 PUFAs on type 2 diabetes mellitus (T2DM).
Study design Time of follow-up Method of evaluation Source of n-3 PUFAs Results
Feskens et al. [17]
175 men  and women aged 64–87 y in a prospective
cohort study
4 years Cross-check dietary history Fish Habitual consumption of small amount of ﬁsh reduced
the risk of T2DM
Meyer  et al. [18]
35988 women  aged 55–69 y in a prospective cohort
study
11 years Frequent food questionnaire Total dietary PUFAs intake Substitution of SFAs with n-3 PUFAs reduced the risk
of T2DM
Vegetable fat inversely related to T2DM
Feskens  et al. [19]
338 middle-aged men  in a prospective cohort study
20 years Cross-check dietary history Fish products SFAs were associated with impaired glucose tolerance
test and T2DM
Fish consumption decreased the risk of T2DM
Kaushik  et al. [20]
152100 women and 42504 men  aged 26–78 y in a
prospective cohort study
14–18 years Frequent food questionnaire Total dietary PUFAs intake SFAs intake positively related to incidence of T2DM
Fish intake was not associated with the risk of T2DM
Brostow  et al. [21]
43176 men  and women without chronic diseases
aged 45–74 y in a prospective cohort study
6 years Frequent food questionnaire Marine and non-marine
sources of n-3 PUFAs intake
Non-marine sources of n-3 PUFAs decreased the risk of
T2DM
Marine sources of n-3 PUFAs were not associated with
the risk of T2DM
Djouss  et al. [22]
36328 women, mean age 54.6 y in a prospective
cohort study
17 years Frequent food questionnaire Total dietary PUFAs intake Higher intake of n-3 PUFAs (≥ 0.2 g n-3 PUFAs/day or ≥
2 servings of ﬁsh/day) increased the risk of T2DM
Van  Woudenberg et al. [23]
4472 men  and women  aged ≥ 55 y in a prospective
cohort study
15 years Frequent food questionnaire Fish and supplement Fish consumption or EPA and DHA supplements were
not associated with T2DM
Patel  et al. [24]
21984 men  and women aged 40–79 y in a
prospective cohort study
10.2 years Frequent food questionnaire Seafood Fish consumption reduced the risk of T2DM
High- dose consumption of shellﬁsh increased the risk
of  T2DM
Hodge  et al. [27]
3737 adults aged 36–72 y in a prospective cohort
study
4 years Assessment of plasma and phospholipids
biomarkers
Total dietary PUFAs intake SFAs and T2DM incidence were directly associated
No relation between n-3 PUFAs and T2DM incidence
Patel  et al. [29]
12403 incident diabetes cases and 16835 adults from
8 European countries in a case-cohort study
3.99 million
person-year
Country-speciﬁc food questionnaires Fish Total ﬁsh and lean ﬁsh consumption were not
associated with incidence of T2DM
Fatty ﬁsh consumption was weakly inversely
associated with incidence of T2DM
Borkman et al. [32]
27 patients aged ≤ 65 y undergoing coronary artery
surgery + 13 normal men  in a cross-sectional study
– Clamp technique for insulin sensitivity
evaluation
Assessment of fatty acid composition in
skeletal muscle
– PUFAs were inversely associated with insulin
resistance in patients
PUFAs were directly associated with insulin sensitivity
in normal subjects
Pan  et al. [33]
52 men aged ≤ 44 in a cross-sectional study
– Clamp technique for insulin sensitivity
evaluation
Assessment of fatty acid composition in
skeletal muscle
– PUFAs were directly associated with insulin action
Iggman  et al. [34]
795 men, mean age 71 y in a cross-sectional study in
ULSM cohort study
– Assessment of biomarkers in adipose tissue
biopsies
Essential PUFAs biomarker Lower amount of PUFAs in adipose tissue was
associated with insulin resistance
306
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Table 2
Clinical studies on effect of n-3 PUFAs on type 2 diabetes mellitus (T2DM).
Study design Type, dose, and source of n-3 PUFAs Timeframe Results
Studies with beneﬁcial effects
Waite et al. [40]
5 subjects in an intervention study
Fish oil supplements (440 mg DHA + 660 mg EPA) 60 days Increase insulin sensitivity
Decrease plasma glucose response
Tsitouras et al. [41]
6 men  and 6 women aged > 60 y in an intervention study
Consumption of 720 g of fatty ﬁsh/week plus 15 ml  of sardine
oil/day
6 weeks fatty ﬁsh
accompanied by 8
weeks sardine oil
Increase in insulin sensitivity
Ramel  et al. [42]
278 overweight and obese subjects in a controlled study of
parallel design
Randomized to 4 energy-restricted diet (−30% of energy
intake)
Control group: no seafood
Lean ﬁsh group: 150 g cod 3 times a week (0.26 g/day n-3
PUFAs)
Fatty ﬁsh group: 150 g salmon 3 times a week (2.1 g/day n-3
PUFAs)
Fish oil group: daily DHA/EPA capsules (1.3 g/day n-3 PUFAs)
8 weeks Consumption of ﬁsh oil decreased fasting blood glucose,
insulin resistance, and plasma triglyceride
Weight loss was also a predictor of improve
Studies  with no effects
Giacco et al. [35]
162 healthy individuals in a parallel design
Subjects randomly divided to 2 groups
Rich in MUFAs
Rich in SFAs
Within each group there was a second randomization to ﬁsh
oil (3.6 g/day) or placebo
3 months No change in insulin sensitivity, insulin secretion or glucose
tolerance in both groups
No change in body weight
Kabir  et al. [36]
27 women with T2DM without hyper-triglyceridemia in a
controlled study of parallel design
3 g/day of ﬁsh oil (1.8 g/day n-3 PUFAs) or placebo (parafﬁn oil) 2 months No change in fasting blood glucose and insulin level
De  Luis et al. [37]
30 subjects with T2DM, mean age 55 y in an intervention
study
930 mg  EPA + 750 mg DHA daily 12 weeks No change in fasting insulin or glucose level
Tierney  et al. [38]
417 participants with metabolic syndrome in a study of
parallel design
Subjects randomly divided to 4 isoenergetic diets
High SFAs
High MUFAs
High-complex carbohydrates supplemented with n-3 PUFAs
(1.2 g/day)
High-complex carbohydrates supplemented with placebo
12 weeks Reducing SFAs had no effect on insulin sensitivity
MUFAs and n-3 PUFAs had no effect on insulin sensitivity
Barre  et al. [43]
18 participants with T2DM, mean age 60 y in a parallel
design
Flaxseed oil, 5 g/day (60 mg/kg/day of -linolenic acid)
Safﬂower, 1 g/day
3 months No effect on fasting blood glucose or insulin level compared
with safﬂower oil
Taylor  et al. [44]
34 participants with T2DM aged 51–54 y in a controlled
study of parallel design
Subjects randomly divided to 3 groups
No ﬂaxseed
Milled ﬂaxseed (13.32 g/day)
Flaxseed oil (12.13 g/day)
12 weeks Milled ﬂaxseed and ﬂaxseed oil increased n-3 PUFAs in plasma
phospholipids
No  effect on glycemic control in well-controlled type 2
diabetic patients
McManus et al. [45]
11 subjects with T2DM, aged 58–64 y in a cross-over study
Fish oil (35 mg/kg/day of 20:5 n-3 and 22:6 n-3)
Linseed oil (35 mg/kg/day of 18:3 n-3)
3 months No signiﬁcant difference observed in weight, fasting glucose
and insulin level
Studies with adverse effects
Mostad et al. [28]
26 subjects with T2DM without hyper-triglyceridemia in a
controlled study of parallel design
Intervention group: 17.6 ml/day ﬁsh oil (5.9 g of n-3 PUFAs)
Control group: 17.8 ml/day corn oil (8.5 g of linoleic acid)
9 weeks Increase in fasting blood glucose and insulin level
Decrease in glucose utilization
Mostad et al. [39]
26 overweight participants aged 40–75 y in a controlled
study of parallel design
Intervention group: 5.9 g/day ﬁsh oil
Control group: 8.5 g/day corn oil (18:2 n-6)
9 weeks Decrease in insulin sensitivity compared with control group
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e concluded that further investigations are needed to conﬁrm
he results of the studies with beneﬁcial effects.
The plant-base n-3 PUFAs which contain more -linolenic acid
han DHA and EPA, showed no beneﬁcial effects on serum glu-
ose and insulin response [43,44]. In another study, a comparison
etween the effects of marine-source n-3 PUFAs and plant-base n-3
UFAs demonstrated no difference in improving insulin sensitivity
etween the mentioned sources [45].
A meta-analysis of 11 clinical trials asserted that n-3 PUFAs
ntervention (dose, 0.138–4 g/day; duration, 8–24 weeks) had no
ffect on insulin sensitivity [46]. In another meta-analysis of 18
andomized, placebo-controlled trials in type 2 diabetic patients,
t was concluded that ﬁsh oil supplementation (range, 3–18 g/day;
ean of intervention duration, 12 weeks) lowered triglycerides,
ut had no effects on glycemic control [47].
Overall, clinical trials have claimed that n-3 PUFAs can amelio-
ate plasma triglycerides, but seem to have no beneﬁcial effect on
nsulin response and glycemic control [35–38,43].  The diet both in
eveloped and developing countries contains higher amount of n-6
UFAs [13,31]. Therefore, the subjects participated in the trials may
equire higher ﬁsh oil doses which are associated with higher n-3
nd lower n-6 PUFAs content, to demonstrate the potential pro-
ective effect of n-3 PUFAs on insulin sensitivity. Additionally, the
ffect of n-3 PUFAs on insulin sensitivity is difﬁcult to be evaluated
ecause of the difﬁculties in ﬁnding a good and reliable marker
or insulin sensitivity. Measurement of fasting blood glucose and
nsulin are not recommended as a good biomarker for insulin sen-
itivity, because they explain less than 40% of insulin sensitivity
ariance observed in a population and 13% of the insulin sensitivity
ariance in normal-weight participants [48]. Some reference meth-
ds such as frequently sampled intravenous glucose tolerance test,
uglycemic-hyperinsulinemic clamp, and insulin suppression test
re more reliable procedures in determining the degree of insulin
ensitivity, but are more expensive and require large number of
articipants to have a meaningful dietary intervention study [49].
Adequate intervention duration is also important to detect a
eal clinical outcome. In most of the mentioned clinical studies
Table 2), the duration of interventions was between 8 and 12
eeks. The authors think that a longer period of intervention dura-
ion is needed to have an appropriate insulin response.
. Conclusion
It is suggested that the epidemiological studies evaluate the pre-
entive effects of dietary n-3 PUFAs on T2DM, whereas, clinical
rials assess their therapeutic effects to ameliorate the condition.
his would suggest avenues of investigations to be pursued.
In evaluating the effect of n-3 PUFAs on insulin sensitivity, it is
ifﬁcult to have a ﬁnal conclusion due to the contradictory results
eported in different trials. The contradicting results might be due
o the fact that several factors such as genetic, life style and different
ietary patterns may  inﬂuence the effect of n-3 PUFAs on insulin
ensitivity and glycemic control. However, because of the beneﬁcial
ffects of n-3 PUFAs on inﬂammation and obesity which are the
isk factors in T2DM, the need for further exact trials on the subject
s evident. The authors think that the acquired results from the
nvestigations concerning no effect of n-3 PUFAs on T2DM might
e due to the following limitations and therefore more clear and
ealistic experiments are needed:
a) Inherent limitations of case–control and cross-sectional studies
due to several sources of bias.
b) Small sample size in some clinical trials.
c) Lack of information about the background diet in some clinical
trials.
[
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d) Limitations on the use of more exact and reliable reference
methods in evaluating insulin sensitivity.
e) Insufﬁcient intervention duration in some clinical studies.
(f) Unrecognized optimum doses of n-3 PUFAs for an acceptable
insulin response.
To overcome some limitations, it is advisable to organize a
database of volunteers who  are currently consuming n-3 PUFAs
supplements and track their health status and serum biochemical
indices over a long period. Moreover, simultaneous effects of n-3
PUFAs with other parameters should be considered.
Dietary approaches to stop hypertension (DASH) eating pattern
can play an important role in reducing inﬂammation as a risk factor
of T2DM. This dietary plan emphasizes the intake of fruits and veg-
etables; and is one of the therapeutic patterns to ameliorate T2DM
[50]. Therefore, the n-3 PUFAs originating from vegetable sources
which are non-expensive alternatives to the marine sources could
be a challenging ﬁeld for further investigations. It should be noted
that there is lack of data on this subject.
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